Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GnRHa Combined With Letrozole vs MA/MPA in Early Endometrial Cancer
NCT05247268Phase 2Active, not recruiting
- Sponsor
- Fudan University
- Start
- Mar 2022
- Primary completion
- Mar 2027
- Modality
- Peptides, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of triprorelin acetate and letrozole in endometrial cancer (EC) (2 arms), sponsored by Fudan University. Primary endpoint: Complete response rates within 16 weeks of treatment. Started Mar 2022; status: active, not recruiting.
02
Drugs
triprorelin acetateletrozole
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT05247268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05247268.